We are ^1000 Amplitude.
The name is new but we, decidedly, are not. We stand proudly on a foundation of deep experience and a demonstrable body of success creating, building, and growing break-out companies.
We are savvy investors and proven company builders who, at the core, are driven to bring the best healthcare innovations to market to help improve the lives of patients one patient at a time.
We have spent decades working with healthcare entrepreneurs to realize their vision of bringing life changing therapies to patients, while delivering superior value to investors.
Most recently, we worked together to lead healthcare venture investing at Canada’s most active venture investor, creating, building and growing globally competitive Canadian healthcare companies. This strong track record has attracted leading institutions as investors in Amplitude.
“The vision of AI in healthcare from the Amplitude team was unique in Canada. They supported the bold step of accelerating growth via acquisition, enabling Imagia to provide one of the leading AI healthcare discovery platform in the world. Their strong network and experience continue to be attractive to new investors & customers who are key to company success.”
“The Amplitude team has been key to our success. As an early investor, they helped construct a great foundational team and then made the moves to add expertise and technology to accelerate our growth and build product lines for Europe and North America.”
“As our first institutional investor, the Amplitude team provided the capital and guidance to enable the company to refine its product strategy and build strong market presence. By always encouraging the company to “think big” and supporting that strategy with capital, they enabled the company to have the confidence to build a world-class product and commercial success.”
“Leadership, guidance and relationships from the Amplitude team were instrumental to our Mezzanine round. It was clear that they shared our vision to create a great company, and to strongly support that vision with the capital they provided, which catalyzed our success since. Their philosophy and commitment to building world-class companies with global impact is refreshingly unique and very much appreciated.”
“As a partner who saw the spark of the idea and provided the kindling to get the fire started, the Amplitude team was key at the company’s origin and their strong and early support was necessary to attract large amounts of external capital that enabled us to attract our leadership team and progress quickly. They were the only Canadian fund to take the early risk with us and see what we could become.”
“As an early institutional investor, the Amplitude team was critical to supporting the company to generate the proof of concept data necessary to attract others. By providing increasing amounts of capital, they enabled us to expand our investor base and secure the growth capital that we needed. Their experience growing companies was invaluable on the board as we built a leadership team to take the company to the next level.”
The Amplitude culture mirrors the outlook of the founders. We are equal parts visionary and pragmatist.
We see the promise that medicine holds. We see a healthcare environment where Canadian entrepreneurs with cutting-edge technologies can enable patients to live longer and happier lives
The Amplitude team is bolstered by a strategic advisory board of the leaders in the Canadian life sciences industy. All company builders with deep experience taking biopharma and medical device companies from idea to exit.
Canada boasts an innovation-rich healthcare ecosystem teeming with world-leading academic and research centres. For too long, however, the capital and expertise necessary to scale potentially game-changing ideas into break-out companies has been largely missing. Our mission is to unite innovators with the necessary capital and our builder vision to create and scale great companies. This is where we focus and thrive.
Where we focus
We believe the future of healthcare lies in today’s tremendous Canadian innovation ecosystem. Our current investment focus is on precision medicine where world-class innovators are driving the future of healthcare by:
- Enhancing the quality and accuracy of diagnoses, delivering more precise treatments, reducing financial costs and side effects.
- Leading the world by combining software and biology by applying artificial intelligence to accelerate therapeutic development, working with next generation imaging to enable robot-assisted surgery, and combining microelectronics and living cells to enable 3D printing of tissues and organs.
- Selecting the right treatment for the right patient with targeted therapies (including antibodies, immunotherapy, and cell & gene therapy).
We direct our efforts towards those opportunities that allow us to create, build, and grow hyper-growth companies with real potential to deliver accelerated growth and build and deliver sector leading value.
We have offices in Montreal, Toronto, and Vancouver, home to world-leading centres of excellence in the field of precision medicine.
The Amplitude Model
Put simply, we exist at the nexus of need and solution. Our mantra is creating, building, and growing companies that bring breakthroughs to patients. The Amplitude team has screened thousands of opportunities during our careers and our first question is always “what problem are you solving?” with the second being, “how big can this be?”
We target companies that are at the acceleration stage, investing capital and leveraging our networks and strategic alliances to help entrepreneurs attract the team and assets needed to enable hyper-growth.
As proven builders, we know how and when to scale teams to propel companies at the acceleration stage. We have forged key strategic partnerships that we leverage on behalf of our portfolio companies to help build critical mass and attract the top talent required to accelerate to hyper growth.
Pre-Amp is Amplitude’s internal engine to discover, incubate, and fund innovation on jet-fuel. Our team of inventors and entrepreneurs partners with academics and company builders around the world to advance proof-of-concept data that will enable breakthrough treatments to patients.
The Amplitude Fellowship is a crucible where Canada’s brightest health-focused PhD candidates, post docs and MDs - many of whom are also inventors - come together each summer to explore “what if” biotech concepts as the first step in creating novel, life-changing health science companies.Learn more
Our portfolio is the best example of how our team helps founders and entrepreneurs create, build, and grow their companies. This hands-on approach is hard-wired in the Amplitude culture as we know that investment capital alone is never enough. The Amplitude team is responsible for the initial investment or significant additional investment and value creation in the following companies while at BDC Capital and now at Amplitude.
Early stage company from the founders of CRISPR Therapeutics.
Gandeeva Therapeutics is revolutionizing the way drugs are designed. Using cryo-electron microscopy, Gandeeva aims to add the unique insights of protein visualization and molecule structure to design of safer and more effective therapies.
Prilenia is focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Their lead program, Pridopidine, is a late stage clinical asset currently in phase 3 trials in Huntington’s disease and ALS. Pridopidine is the most advanced candidate in clinical development for maintenance of functional capacity in Huntington’s Disease.
Congruence is developing a unique computational platform utilizing machine learning to focus on protein stabilization and identifying novel small molecules to treat rare diseases.
Celsius is leveraging the power of single cell genomics to advance precision medicines against complex autoimmune diseases and cancer. Using the world’s largest database of longitudinal, clinically annotated patient samples, Celsius uses machine learning to identify novel targets and unique patient biomarkers in a variety of complex diseases.
Valence is leveraging their leading AI small molecule design platform with exceptional chemistry and biology expertise to design better drugs in a variety of diseases.
Drugbank is building one of the world’s largest databases of structured drug and target information used by thousands of institutions, researchers and companies globally.
Notch is a leader in the development of cellular therapeutics originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. The company has unlocked the ability for large-quantity production of T-cells and other cells from any source of stem cells to bring best-in-class cell therapy products to thousands of patients.
Through the collaborative work of world-class experts, Thryv Therapeutics has been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition. The Thryv Therapeutics’ portfolio, previously LQT Therapeutics, has evolved to include the treatment of resistant and rare cancers.
Radiant Biotherapeutics is advancing a first in class biologic therapy platform that combines multi-specificity and multi-valency on a single molecule to create transformative therapies. Built upon the IgG framework, Multabodies are plug and play, with superior potency over existing monoclonal antibodies and antibody cocktails.
Deep Genomics is leveraging a powerful artificial intelligence platform to identify new disease targets and accelerate drug discovery and drug development. The company is developing a rich pipeline of disease modifying oligonucleotide-based therapeutics for previously unaddressed rare diseases.
Repare Therapeutics(IPO June 2020. NASDAQ: RPTX)
Repare, a 2017 FierceBiotech Fierce 15 company, is leveraging deep expertise in synthetic lethality and DNA repair to develop precision oncology drugs targeting tumour-specific vulnerabilities. Repare is combining a proprietary, high throughput, CRISPR-enabled discovery platform with high-resolution protein crystallography, computational biology, and clinical informatics to build an innovative therapeutic pipeline.
Milestone Pharmaceuticals(IPO May 2019. NASDAQ: MIST)
Milestone is developing a self-administered treatment for paroxysmal supraventricular tachycardia (PSVT) episodes and other episodic conditions. We believe that self-administered treatment at home has the potential to significantly improve the quality of life for patients and reduce the cost of care by avoiding emergency room visits. We were one of the first institutional investors in the company and have advanced the company to the initiation of a Phase III study and an IPO on NASDAQ.
Profound Medical(IPO June 2015. TSX: PRN)
Profound has developed real-time MR-guidance as the imaging platform, and ultrasound as the energy source for delivering non-invasive ablative tools to clinicians. Its lead product is TULSA-PRO®, which combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control that is designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. We believe that surgical care is rapidly moving to integrate real-time imaging technology, robotics and human experience to reduce and remove limitations to surgeons. We were one of the first institutional investors in the company and have grown it to commercial stage and a public market listing.
Zymeworks(IPO April 2017. NYSE: ZYME)
Zymeworks’ suite of complementary therapeutic platforms and its fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated therapeutics. We believe that Zymeworks’ platform enables the company and its partners to develop highly effective, targeted therapeutics that can deliver significantly improved patient health. We led the mezzanine round that enabled the acquisition of Kairos and the company’s subsequent IPO.